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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors with a dismal prognosis 
and no effective conservative therapeutic strategies. Although it is demonstrated that histone deacetylases (HDACs), 
especially the class I HDACs HDAC1, 2 and 3 are highly expressed in this disease, little is known about HDAC isoenzyme 
specific functions.
Results: Depletion of HDAC2, but not HDAC1, in the pancreatic cancer cell lines MiaPaCa2 and Panc1 resulted in a 
marked sensitization towards the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Correspondingly, 
the more class I selective HDAC inhibitor (HDACI) valproic acid (VPA) synergized with TRAIL to induce apoptosis of 
MiaPaCa2 and Panc1 cells. At the molecular level, an increased expression of the TRAIL receptor 1 (DR5), accelerated 
processing of caspase 8, pronounced cleavage of the BH3-only protein Bid, and increased effector caspase activation 
was observed in HDAC2-depleted and TRAIL-treated MiaPaCa2 cells.
Conclusions: Our data characterize a novel HDAC2 function in PDAC cells and point to a strategy to overcome TRAIL 
resistance of PDAC cells, a prerequisite to succeed with a TRAIL targeted therapy in clinical settings.
Background
The incidence of pancreatic ductal adenocarcinoma
(PDAC) is only about 10 in 105, but it is the fourth leading
cause of cancer-related death with a 5-year survival rate
beyond 5% [1]. As there is no significant improvement in
patient survival over the last decades [2] and biologicals
like the epidermal growth factor receptor (EGFR) inhibi-
tor erlotinib are only active in a subset of patients [3],
there is a need to develop new rational based therapeutic
strategies in preclinical settings.
Histone deacetylases (HDACs) deacetylate the ε-amino
group of lysines located at the N-terminal tail of histones,
which leads to a repressive chromatin formation (hetero-
chromatin) and the suppression of gene expression [4]. In
addition to the condensation of chromatin, HDACs
deacetylate various proteins to regulate their function.
Many of these proteins are transcription factors, such as
p53, C/EBPβ, NF-κB and STATs. Therefore changes in
the transcriptome upon HDAC inhibitor (HDACI) treat-
ment can be due to a direct modulation of the "histone
code" or the consequence of a rather indirect modulation
of signaling pathways and transcription factor activities
[5-7]. The eighteen deacetylases encoded in the mamma-
lian genome are grouped into class I (HDAC 1, 2, 3 and
8), class II (HDAC 4, 5, 6, 7, 9 and 10), class III (SIRT 1-7)
and class IV (HDAC11) enzymes [4]. In tumors, HDACs
are involved in the regulation of proliferation, apoptosis,
differentiation, migration and angiogenesis [8] and are
hence promising targets for therapeutic intervention. In
PDAC, the contribution of HDACs towards the control of
proliferation, apoptosis and metastasis is clearly docu-
mented [9]. Consistently, various HDACI were developed
over the last years and are now tested in numerous clini-
cal trials [10]. However, HDACI as monotherapeutics are
only effective in a defined subset of hematological tumors
and there are several evidences that rational- and molec-
ular-defined HDACI-based combination therapies are
more useful for the treatment of solid cancers [11]. Defin-
ing suitable HDACI-based combinations is especially
important in PDAC since a recent phase II clinical trial
failed to demonstrate effectiveness of the weak HDACI
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CI-994 combined with the current standard chemothera-
peutic gemcitabine [12].
In this study we show that specific depletion of
HDAC2, but not HDAC1, sensitizes PDAC cells towards
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis, suggesting a new therapeu-
tic strategy.
Results
HDAC2 depletion sensitizes PDAC cells towards TRAIL-
induced apoptosis
We recently observed the HDAC2 mediated control of
the DNA-damage response in PDAC cells [13]. To inves-
tigate HDAC2 function in the extrinsic apoptotic path-
w a y ,  w e  u s e d  H D A C 2 - s p e c i f i c  s i R N A  i n  P D A C  c e l l s
(figure 1A). As shown in figure 1B, HDAC2-depleted
MiaPaCa2 and Panc1 cells revealed a distinctly decreased
viability after the treatment with TRAIL as compared to
control siRNA transfected cells. Consistently, the TRAIL-
induced apoptotic fraction was significantly increased in
a dose-dependent manner in HDAC2-depleted
MiaPaCa2 and Panc1 cells (figure 1C). Increased apopto-
sis induction by TRAIL in MiaPaCa2 and Panc1 cells was
further validated using western blots for cleaved PARP
(figure 1D). In addition, increased PARP cleavage in
HDAC2 siRNA transfected DanG and BxPc3 cells was
observed, arguing for a general control of extrinsic apop-
totic signaling by HDAC2 in PDAC cells (data not
shown).
Valproic acid sensitizes PDAC cells towards TRAIL-induced 
apoptosis
Since valproic acid (VPA) is a more class I specific
HDACI and known to deplete HDAC2 via a proteasomal
pathway [14,15], we validated the results obtained with
functional genomics using VPA. We used VPA at a con-
centration of 1.5 mM, which is achievable in therapeuti-
cal settings and has no influence on PDAC cell
proliferation or viability [13]. Co-treatment of MiaPaCa2
and Panc1 cells with TRAIL and VPA lead to a signifi-
cantly reduced viability in a dose-dependent fashion,
compared to cells treated with TRAIL alone (figure 2A).
In line, an increased apoptotic fraction was observed in
VPA and TRAIL co-treated MiaPaCa2 and Panc1 cells
(figure 2B), reproducing the results obtained with RNA
interference (RNAi) and suggesting that HDAC2 attenu-
ates TRAIL-induced apoptosis in PDAC cells.
TRAIL mediated apoptosis is not influenced by HDAC1 in 
PDAC cells
Since HDAC-dependent non-redundant functions are ill
defined, we tested whether HDAC1-depletion also sensi-
tizes for TRAIL-induced apoptotsis. Transfection of
HDAC1 siRNA into MiaPaCa2 and Panc1 cells resulted
in a specific knockdown of HDAC1, whereas HDAC2
expression was not affected (figure 3A). Nevertheless,
TRAIL-induced loss of viability of MiaPaCa2 and Panc1
cells was not changed in HDAC1 siRNA transfected cells
compared to control siRNA transfected cells (figure 3B).
Furthermore, no increase in the apoptotic fraction was
observed in HDAC1-depleted and TRAIL-treated
MiaPaCa2 and Panc1 cells in comparison to control
siRNA transfected cells (data not shown). This argues
that HDAC2 is specifically involved in the regulation of
TRAIL induced apoptosis, independently of HDAC1.
HDAC2-dependent regulation of the BH3-only protein 
NOXA is not involved in HDAC2-depletion mediated TRAIL 
sensitization
Recently we observed that depletion of HDAC2 results in
an increased expression of the pro-apoptotic BH3-only
protein NOXA in PDAC cells [13]. To investigate the
influence of NOXA on the HDAC2-dependent sensitiza-
tion towards TRAIL-induced apoptosis, we simultane-
ously transfected HDAC2- and NOXA-specific siRNAs
into MiaPaCa2 cells. As shown in figure 4A, upregulation
of NOXA mRNA by the depletion of HDAC2 was signifi-
cantly inhibited, when the cells were transfected with
both siRNAs. Furthermore, HDAC2-depletion mediated
sensitization of MiaPaCa2 cells towards TRAIL-induced
apoptosis was not changed in HDAC2 and NOXA siRNA
co-transfected cells (figure 4B), demonstrating that
HDAC2-mediated sensitization towards death receptor
induced apoptosis is independent of NOXA.
HDAC2 regulates the TRAIL receptor DR5 in MiaPaCa2 cells
Recent evidence suggests that HDACs can alter gene
expression by the direct deacetylation of ε-amino-lysin
groups at the N-terminal tails of histones and/or by the
direct influence on various signaling pathways [6]. To dis-
criminate between both possibilities we transfected
MiaPaCa2 cells with a control and a HDAC2-specific
siRNA and treated the cells with TRAIL or a combination
of TRAIL and actinomycin D to inhibit TRAIL signaling-
induced transcription. As shown in figure 5A, TRAIL-
induced caspase 3/7 activation was significantly
increased in HDAC2-depleted MiaPaCa2 cells. Further-
more, blocking transcription in control and HDAC2
siRNA transfected MiaPaCa2 cells resulted in an
increased caspase 3/7 activity, arguing that the TRAIL-
induced transcription functions mainly to restrain death-
receptor-induced apoptosis. Nonetheless, caspase 3/7
activity was significantly higher in TRAIL and actinomy-
cin D co-treated HDAC2-depleted MiaPaCa2 cells than
in TRAIL and actinomycin D co-treated control siRNA
transfected cells, indicating that a change in the gene
expression after HDAC2 depletion or a mechanism not
requiring transcription, independently of TRAIL-Schüler et al. Molecular Cancer 2010, 9:80
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induced transcription, at least contributes to the
increased sensitivity of HDAC2-depleted MiaPaCa2 cells
to TRAIL. In line with the increased activity of caspase 3/
7 we observed an accelerated cleavage of caspase 8 in
HDAC2-depleted and TRAIL-treated MiaPaCa2 cells,
which correlated with the appearance of cleaved PARP as
an indirect measurement of effector caspase activity (fig-
ure 5B and 5C). Similar results were observed in VPA
treated MiaPaCa2 cells (data not shown). Furthermore,
we detected a distinctly increased cleavage of Bid in
HDAC2-depleted and TRAIL-treated MiaPaCa2 cells,
compared to control siRNA transfected cells (figure 5D).
In transcriptome profiles of HDAC2-depleted PDAC
cells, which we have recently published [13], the TRAIL
receptor DR5 was 2.2 fold upregulated in MiaPaCa2 cells
and marginally increased in Panc1 cells. As shown in fig-
ure 5D and 5E, increased DR5 protein expression was
detected in HDAC2-depleted MiaPaCa2 cells. In con-
trast, no change in the expression of DR4, c-Flip, XIAP ,
cIAP1, cIAP2, mcl1 or survivin was observed in HDAC2-
depleted MiaPaCa2 cells (figure 5D). A slight but consis-
tent upregulation of bclXL  was observed in HDAC2-
Figure 1 HDAC2 depletion sensitizes PDAC cells towardsTRAIL. A) Western blot analysis of HDAC2 and HDAC1 48 hours after the transfection of 
MiaPaCa2 (upper panel) and Panc1 cells (lower panel) with a control siRNA or a HDAC2-specific siRNA. β-actin controls equal protein loading. B) 
MiaPaCa2 (left graph) and Panc1 cells (right graph) were transfected with a control siRNA or a HDAC2-specific siRNA. 48 hours after the transfection 
the cells were treated with increasing doses of TRAIL as indicated for additional 24 hours or left as an untreated control. Viability was determined using 
MTT assays (Student's t-test: * p < 0.05 versus controls). C) MiaPaCa2 (left graph) and Panc1 cells (right graph) were transfected with a control siRNA 
or a HDAC2-specific siRNA. 48 hours after transfection the cells were treated with increasing doses of TRAIL (6.25, 12.5, 25, 50 and 100 ng/ml) for ad-
ditional 24 hours or left as an untreated control. Apoptotic cells were quantified by fluorescence microscopy after Hoechst staining (Student's t-test: 
* p < 0.05 versus controls). D) MiaPaCa2 and Panc1 cells were transfected with a control siRNA or a HDAC2-specific siRNA. 48 hours after the transfec-
tion the cells were treated with 25 ng/ml TRAIL for additional 24 hours or left as an untreated control. Cleaved PARP western blotting was used as an 
indirect measurement of caspase activity. β-actin controls equal protein loading.Schüler et al. Molecular Cancer 2010, 9:80
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depleted MiaPaCa2 cells (figure 5D). Fitting to an
increase in apoptosis induced by TRAIL in HDAC2-
depleted MiaPaCa2 cells, we observed a more pro-
nounced elimination of c-Flip after the TRAIL treatment
in HDAC2 siRNA transfected MiaPaCa2 cells (figure 5D).
In contrast to MiaPaCa2 cells, upregulation of DR5 pro-
tein expression after HDAC2 depletion was not observed
in Panc1 cells (figure 5E). Consistently, DR5 cell surface
expression was slightly increased in MiaPaCa2 cells, but
not in Panc1 cells (figure 5F). Together, these data argue
that HDAC2-dependent sensitization towards TRAIL-
induced apoptosis works upstream of Bid in MiaPaCa2
cells.
Discussion
Deregulation of apoptosis is a hallmark of cancer and is
an important cause of therapeutic failure of conventional
chemotherapeutics [16,17]. Apoptosis can be initiated by
the extrinsic death receptor-dependent as well as the
intrinsic mitochondrial pathway and various mechanisms
of resistance working on several levels were described in
PDAC [18,19]. Triggering of death-receptors, like the
CD95 receptor or TRAIL receptors, results in the activa-
tion of the initiator caspase 8 via the death-inducing sig-
naling complex (DISC) with subsequent activation of
effector caspases. In PDAC cells, which are type II cells,
active caspase 8 cleaves the BH3-only protein Bid, which
Figure 2 The HDACI VPA sensitizes PDAC cells towards TRAIL-induced apoptosis. A) MiaPaCa2 (left graph) and Panc1 cells (right graph) were 
pre-treated with VPA or were left as an untreated control. After 48 hours the cells were treated with TRAIL or the combination of TRAIL and VPA for 
additional 24 hours or were left as an untreated control. TRAIL was used at concentrations of 6.25, 12.5, 25, 50 and 100 ng/ml. Viability was measured 
by MTT assays (Student's t-test: * p < 0.05 versus controls). B) MiaPaCa2 (left graph) and Panc1 cells (right graph) were pre-treated with VPA or were 
left as an untreated control. After 48 hours the cells were treated with TRAIL or the combination of TRAIL and VPA for additional 24 hours or were left 
as an untreated control. TRAIL was used at concentrations of 6.25, 12.5, 25, 50 and 100 ng/ml. Apoptotic cells were quantified by fluorescence micros-
copy after Hoechst staining (Student's t-test: * p < 0.05 versus controls).Schüler et al. Molecular Cancer 2010, 9:80
http://www.molecular-cancer.com/content/9/1/80
Page 5 of 10
augments the activation of the caspase cascade via the
mitochondrium [20,21]. Due to their selective toxicity
towards cancer cells, TRAIL receptor agonists are prom-
ising cancer therapeutics and currently tested in clinical
trials [21]. Furthermore, the observation that high TRAIL
expression was correlated with an increased apoptotic
index in the human pancreas argues that a TRAIL-based
therapy might be a feasible strategy for the treatment of
PDAC [22,23]. However, human primary tumor cells
often resist TRAIL-induced apoptosis and PDAC cells
reveal a relatively high half maximal inhibitor concentra-
tion (IC50) for TRAIL although they express the TRAIL
receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) as well
as relevant mediators of the TRAIL receptor signaling
pathway [24-26]. Therefore, strategies to sensitize PDAC
cells towards TRAIL and to counteract resistance mecha-
nisms are of value for defining new therapies for the
treatment of PDAC.
In this study we show that the more class I selective
HDACI VPA sensitizes PDAC cells towards TRAIL-
induced apoptosis. Furthermore, we demonstrate that
HDAC2, which is highly expressed in human PDACs
[13,27], controls resistance towards TRAIL. These results
in combination with the high expression of HDAC2 in
many solid tumors [28] and the recent observation of
HDAC2-dependent sensitization of breast and pancreatic
cancer cells towards topoisomerase II inhibitors [13,29],
of breast cancer cells towards antihormonal therapy [30]
and of colon cancer cells towards TNFα [31], character-
izes HDAC2 as an important therapeutic target. Further-
more, HDAC2 contributes to EMT, one initial
mechanism of metastasis, by the downregulation of E-
cadherin in pancreatic cancer cells [32]. Altogether, these
data may base the development of HDAC2 isoenzyme
specific inhibitors with increased inhibitory capacity and
lower toxicity compared to current HDACI [33].
Several TRAIL resistance mechanisms working at the
level of the TRAIL receptors, the TRAIL DISC, the inhib-
itor of apoptosis proteins (IAPs) or the mitochondrium
were described in PDAC cells [18,19]. However, consis-
Figure 3 HDAC1 is not involved in the regulation of TRAIL-induced apoptosis in PDAC cells. A) Western blot analysis of HDAC1 and HDAC2 48 
hours after the transfection of MiaPaCa2 (left panel) and Panc1 cells (right panel) with a control siRNA or a HDAC1-specific siRNA. β-actin controls equal 
protein loading. B) MiaPaCa2 (left graph) and Panc1 cells (right graph) were transfected with a control siRNA or a HDAC1-specific siRNA. 48 hours after 
the transfection the cells were treated with 50 ng/ml TRAIL for additional 24 hours or left as an untreated control. Viability was determined using MTT 
assays (Student's t-test: * p < 0.05 versus controls).Schüler et al. Molecular Cancer 2010, 9:80
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tent with our recent transcriptome profiling [13], we were
not able to detect a clear downregulation of c-Flip, XIAP,
cIAP1, cIAP2, mcl1, bclXL or survivin at the protein level
after depletion of HDAC2, although an involvement of
these proteins in the control of TRAIL resistance was
described [26,34-43]. Using the HDACI butyrate, Natoni
et al. described a HDAC-dependent control of sensitivity
of PDAC cells towards Fas-induced apoptosis. At the
molecular level the authors observed a reduced expres-
sion of bclXL and c-Flip after the treatment with butyrate
[44]. The failure to detect downregulation of bclXL and c-
Flip after the sole HDAC2 depletion points to compensa-
tory mechanisms working to maintain expression of these
genes in PDAC cells. Nonetheless, our results are consis-
tent with recent observations in HCT116 colon cancer
cells, where HDACI treatment or depletion of HDAC2,
but not HDAC1, sensitizes towards TNFα-induced apop-
tosis [31]. Here, a contribution of NF-κB in the HDAC2-
dependent sensitization was proposed, since HDAC2 siR-
NAs reduce the TNFα mediated activation of a NF-κB
luciferase reporter gene [31]. Consistently, a recent study
reveals that treatment of the PDAC cell line Panc1 with
the HDACI SAHA reduces basal binding of RelA to a
consensus κB oligonucleotide [27]. Alike, we observed
dependency of the basal NF-κB transcriptional activity on
the presence of HDAC2 in PDAC cells (data not shown).
The observation that basal, but not induced, NF-κB activ-
ity contributes to TRAIL resistance of PDAC cells [45]
and that inhibition of NF-κB by the super-inhibitor delta-
N-IκBα [46] or a p65 siRNA [47] resulted in profound
sensitization towards TRAIL-induced apoptosis in PDAC
cells, might point to the contribution of NF-κB in our
model system. However, we cannot rule out NF-κB-inde-
pendent mechanisms at the moment and the ultimate
clarification awaits further experiments beyond the scope
of the article.
HDACI sensitize cancer cells towards TRAIL and sev-
eral mechanisms, like upregulation of TRAIL and TRAIL
receptors, downregulation of c-Flip, XIAP or members of
the anti-apoptotic bcl2 family members as well as the
modulation of NF-κB activity were shown to contribute
[48,49]. As observed in many studies using HDACI to
sensitize towards TRAIL, we observed a slight upregula-
tion of DR5 protein abundance and cell surface expres-
sion in MiaPaCa2 cells after the depletion of HDAC2.
The notice that HDACI-dependent TRAIL sensitization
is independent of DR5 [50] and that DR5 regulation was
not observed in Panc1 cells points to an alternative
HDAC2 regulated mechanism contributing to the sensiti-
zation of PDAC cells. The demonstration of accelerated
TRAIL-induced Bid cleavage after the depletion of
HDAC2 argues that an event upstream of Bid is under
Figure 4 HDAC2-dependent regulation of NOXA does not contribute to TRAIL sensitization. A) Quantitative NOXA and HDAC2 mRNA expres-
sion analysis in MiaPaCa2 cells after the transfection of a control, a HDAC2-specific or the combination of HDAC2- and NOXA-specific siRNAs. Total 
RNA was prepared 48 hours post-transfection. NOXA and HDAC2 mRNA levels were quantified using real-time PCR analysis and normalized to cyclo-
philin expression levels (Student's t-test: * p < 0.05 versus controls). B) MiaPaCa2 cells were transfected with a control siRNA, a HDAC2-specific siRNA 
or co-transfected with a HDAC2- and NOXA-specific siRNA as indicated. 48 hours after the transfection the cells were treated with 30 ng/ml TRAIL for 
additional 24 hours or left as an untreated control. Apoptotic cells were quantified by fluorescence microscopy after Hoechst staining (Student's t-
test: * p < 0.05 versus controls).Schüler et al. Molecular Cancer 2010, 9:80
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Figure 5 HDAC2-dependent regulation of DR5 in MiaPaCa2 cells. MiaPaCa2 cells were transfected with a control or a HDAC2-specific siRNA as 
indicated. A) 48 hours after the transfection the cells were treated with 15 ng/ml TRAIL or a combination of TRAIL and actinomycin D (1 μg/ml) for 
additional 2 hours. Afterwards caspase 3/7 activity was measured (Student's t-test: * p < 0.05 versus controls). B) 48 hours after the transfection the 
cells were treated with 30 ng/ml TRAIL as indicated. Western blot determines caspase 8 (55/50 kD), caspase 8 cleavage products (migrating at 40/36 
kD and 23 kD), cleaved PARP and HDAC2 expression. β-actin controls equal protein loading. C) MiaPaCa2 cells were treated as in B). The caspase 8 
cleavage product migrating at 40/36 kD was quantified in control and HDAC2 siRNA transfected MiaPaCa2 cells 3 hours after the TRAIL treatment in 
four independent experiments (Student's t-test: * p < 0.05 versus controls). D) 48 hours after the transfection the cells were treated with 30 ng/ml 
TRAIL for 6 hours. Western blot determines DR5, DR4, Bid, c-Flip, XIAP, cIAP1, cIAP2, mcl1, bclXL, survivin and HDAC2 expression. β-actin controls equal 
protein loading. E) Panc1 (left graph) and MiaPaCa2 cells (right graph) were transfected as indicated. Western blot determines DR5 and HDAC2 ex-
pression 48 hours after the transfection. β-actin controls equal protein loading. F) Panc1 (left graph) and MiaPaCa2 cells (right graph) were transfected 
as indicated. 48 hours after the transfection DR5 surface expression was determined by FACS analysis (Student's t-test: * p < 0.05 versus controls).Schüler et al. Molecular Cancer 2010, 9:80
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HDAC2 control in PDAC cells. Accordingly, HDACI-
dependent increased recruitment of the DISC compo-
nent Fas-associated death domain protein (FADD) to the
T R A I L - R 1  w a s  r e c e n t l y  s h o w n  t o  p l a y  a  r o l e  i n  t h e
HDACI-mediated sensitization of CLL cells to TRAIL
[51]. Although accelerated DISC formation and function
after HDAC2 depletion is an attractive possibility, it is
currently not known whether HDAC2 can control DISC
formation and proof of this alternative explanation awaits
additional experiments.
Conclusions
In summary, we have described a novel non-redundant
HDAC2 function in PDAC cells that provides the ratio-
nale for further preclinical evaluation of a HDACI
(HDAC2 isoenzyme-specific) and TRAIL combination
therapy. Furthermore, our experiments point to a way to
overcome TRAIL resistance of PDAC cells, needed to
succeed with a TRAIL targeted therapy in clinical set-
tings.
Methods
Cell culture, siRNA transfection and reagents
The pancreatic cancer cell lines MiaPaCa2 and Panc1
were cultivated as recently described [13]. Valproic acid
(VPA) and TRAIL were purchased from EMD (EMD Bio-
sciences, San Diego, CA, USA). Actinomycin D was from
Sigma-Aldrich (Sigma-Aldrich, Munich, Germany).
Untreated controls received vehicle alone. Double-
stranded siRNAs were transfected at a final concentration
of 50 nM using oligofectamine (Invitrogen, Karlsruhe,
Germany) according to the manufacturer's protocol. siR-
NAs were purchased from Eurofins, Ebersberg, Germany.
Sequences of the used siRNAs were: control siRNA 5' C A
G T C G C G T T T G C G A C T G G dtdt 3', HDAC2
siRNA 5' G C C T C A T A G A A T C C G C A T G dtdt 3
', HDAC1 siRNA 5' G C A G A T G C A G A G A T T C A
A C dtdt 3', NOXA siRNA 5' G G A A G T C G A G T G T
G C T A C T dtdt 3'. For the simultaneous transfection of
siRNAs directed against two different genes, the total
amount of siRNA (100 nM) was kept constant using con-
trol siRNA.
Statistical methods
All data were obtained from at least three independent
experiments performed in triplicate, and the results are
presented as mean and standard error of the mean
(S.E.M.). To demonstrate statistical significance a two-
tailed Student's t-test was used. p-values are indicated
and * denotes a p-value of at least < 0.05.
Quantitative Reverse-Transcriptase PCR
Total RNA was isolated from pancreatic carcinoma cell
lines using the RNeasy kit (Qiagen, Hilden, Germany) fol-
lowing the manufacturer's instructions. Quantitative
mRNA analyses were performed as previously described
using real-time PCR analysis (TaqMan, PE Applied Bio-
systems, Norwalk CT) [52,53]. Expression levels were
normalized using cyclophilin. Primer sequences were as
follows: cyclophilin-fw 5' A T G G T C A A C C C C A C
C G T G T 3'; cyclophilin-rev 5' T C T G C T G T C T T T
G G G A C C T T G T C 3'; HDAC2-fw 5' A G C A T C A
G G A T T C T G T T A C G T T A A T G A 3'; HDAC2-
rv 5' C A A C A C C A T C A C C A T G A T G A A T A T
C T 3'; NOXA-fw 5' C G G A G A T G C C T G G G A A
G A A 3'; NOXA-rev 5' C C A A A T C T C C T G A G T
T G A G T A G C A 3'.
Total cell lysates and Western blot
Whole cell lysates were prepared and western blots were
done as recently described [52,53]. The following anti-
bodies were used: DR4, DR5 (ProScience Inc., Poway, CA,
USA); HDAC2 (H-54, sc-7899) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA); XIAP, cIAP1, cIAP2, survivin
(R&D Systems, Minneapolis, MN, USA); Bid, bclXL (Cell
Signaling Technology Inc., Danvers, MA, USA); NOXA,
mcl1 (Alexis Biochemicals, San Diego, CA, USA); c-Flip,
cleaved PARP, caspase 8 (BD Biosciences, Heidelberg,
Germany); HDAC1 (Upstate/Millipore, Billerica, MA,
USA); β-actin (Sigma-Aldrich, Munich, Germany). One
representative western blot out of at least three indepen-
dent experiments is shown. Western blots were quanti-
fied using Odyssey Infrared Imaging System (LI-COR
Biosciences, Bad Homburg, Germany), assuring mea-
surements in the linear range.
MTT- and Caspase 3/7-assay
Viability of the cells was measured using MTT-assays
performed according to the manufacturer's protocol
(Roche Applied Science, Mannheim, Germany). Caspase
3/7 activity was determined using Promega's Caspase-
Glo 3/7 assay according to the manufacturer's instruc-
tions (Promega, Madison, WI, USA).
Analysis of cell surface expression of DR5
Cells were transfected as indicated. After 48 h cells were
trypsinized, washed once with PBS and suspended in PBS
containing 2 μg/ml primary antibody (anti-DR5; R&D
Systems, Minneapolis, USA) or control IgG. Cells were
stained on ice for 60 min, then washed with 3 ml cold PBS
and incubated with the secondary antibody (1:100 dilu-
tion PE-conjugated goat anti-mouse F(ab')2 anti-
IgG+IgM (Jackson ImmunoResearch, Suffolk, England))
for 60 min, on ice, in the dark. After an additional wash
with 3 ml cold PBS, cells were suspended in 1 ml cold
FACS buffer and 10.000 cells per sample were analyzed
using fluorescence flow cytometry (Galaxy Argon Plus,Schüler et al. Molecular Cancer 2010, 9:80
http://www.molecular-cancer.com/content/9/1/80
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Dako, Glostrup, Denmark) and results were analysed
with the FLOMAX software (Dako).
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